Patrick is the managing editor of PharmaBoardroom, writing and editing stories on all things healthcare and the life sciences. The holder of a Master's Degree in International Relations, Patrick has contributed to over 40 country reports and is a fluent Mandarin speaker.
The biggest recent stories from French healthcare and the life sciences, including Sanofi’s deal to buy immunology biotech Blueprint; the largest from a European pharma this year. Elsewhere Servier is…
Eye health is vital to everyday life, yet it remains heavily underfunded compared to fields like cancer or diabetes. While global spending on oncology is set to reach USD 440…
Rare diseases, by definition, only affect small patient populations. However, when the more than 7,000 known rare conditions are taken together, their impact on health, societies, and economies is enormous.…
The latest pharma and healthcare news from the dynamic Middle East and Africa market, which reached USD 32.6 billion in value last year according to IQVIA. With supply security of…
Will a new ‘Critical Medicines Act’ go far enough to ensure Europe’s resilience to future health crises? A Continent at Risk The COVID-19 pandemic exposed serious vulnerabilities in the…
A whistlestop tour though the latest news from pharma in Asia, taking in the American gene sequencing giant caught in the crosshairs of the US-China tariff row, the ADC-focused Singaporean…
The US pharmaceutical industry is scrambling to align with President Donald Trump’s policy agenda, but may not get all it wishes for… In its first few weeks in power,…
Rare diseases, by definition, only affect small patient populations. However, when the more than 7,000 known rare conditions are taken together, their impact is enormous. Rare disease patients, for example,…
Mexico has firmly established itself as a regional powerhouse in medical device manufacturing. The country is home to the second-largest medtech market in Latin America, employs around 160,000 people in…
A new book by two pharma industry experts offers the first truly global perspective on the complexities of market access. Even the most innovative drug is useless if patients…
Three leading lights from biopharma, policy, and research come together in Riyadh to discuss the current treatment and prevention landscape for Alzheimer’s disease. As people live longer, the threat…
Since raising USD 289 million in its Spring 2020 Hong Kong IPO, InnoCare Pharma has had a remarkable rise. Led by a team of Big Pharma veterans and now also…
See our Cookie Privacy Policy Here
